Acurx Pharmaceuticals (ACXP) Stock Analysis

What Acurx Pharmaceuticals does

Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.

Key metrics

ETFs linked to ACXP

Broad-market and Healthcare sector ETFs an investor holding Acurx Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ACXP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Acurx Pharmaceuticals?

Acurx Pharmaceuticals trades under the ticker ACXP on NASDAQ.

Which exchange is ACXP listed on?

ACXP is listed on NASDAQ.

What sector does Acurx Pharmaceuticals operate in?

Acurx Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ACXP in a portfolio?

PortView shows ACXP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.